Products for Research Use Only
RegisterLogin

Xirestomig

CAT: 0804-HY-P990778-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P990778-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Xirestomig (ATG-101) is a tetravalent "2+2″ PD-L1x4-1BB bispecific antibody. Xirestomig binds PD-L1 and 4-1BB concurrently, with a greater affinity for PD-L1, and potently activated 4-1BB+ T cells when cross-linked with PD-L1-positive cells. Xirestomig activates exhausted T cells upon PD-L1 binding. Xirestomig displays potent antitumor activity in numerous in vivo tumor models, including those resistant or refractory to immune checkpoint inhibitors (ICIs) [1].
CAS Number
2756879-35-1
Product Name Alternative
ATG-101
UNSPSC
12352203
Target
PD-1/PD-L1; TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Apoptosis; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/xirestomig.html
Purity
98.437
References & Citations
[1]Yuwen H, et al. ATG-101 Is a Tetravalent PD-L1x4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1-Directed 4-1BB Activation. Cancer Res. 2024 May 15;84 (10) :1680-1698.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported

Alternative Products

CatalogName
HC336176-01Research Grade Xirestomig
E55B1354Xirestomig (Reference antibody)
GTR18695803-01Xirestomig Human Monoclonal Antibody
A137038Xirestomig Biosimilar (Monoclonal, IgG1-scFv_L2 dimer)
PX-TA2151-01Xirestomig Biosimilar - Anti-Tumor necrosis factor receptor superfamily member 9; CD274 mAb - Research Grade

Popular Products